# OnCo record nektar-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nektar-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nektar-therapeutics" ;
  schema:name "Nektar Therapeutics"@en ;
  schema:alternateName "Nektar"@en ;
  schema:description "Nektar is a San Francisco biotechnology company whose polymer conjugation chemistry underlies several approved drugs and whose engineered interleukin-2, bempegaldesleukin, failed in phase 3 with nivolumab in 2022."@en ;
  schema:url <https://onco.cc/companies/nektar-therapeutics/>, <https://www.nektar.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nektar_Therapeutics> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17114308> ;
  schema:citation <https://www.nektar.com>, <https://clinicaltrials.gov/search?lead=Nektar%20Therapeutics>, <https://en.wikipedia.org/wiki/Nektar_Therapeutics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/bempegaldesleukin/> ;
  onco:companies <https://onco.cc/companies/bms/> .